Quick Answer
PLUS THERAPEUTICS, INC. reported R&D Expense of $8.38 million for fiscal year 2025.
PLUS THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $8.38M | -20.8% |
| 2024 | $10.58M | +9.2% |
| 2023 | $9.69M | -0.1% |
| 2022 | $9.70M | +259.2% |
| 2020 | $2.70M | -49.7% |
| 2019 | $5.37M | -2.9% |
| 2018 | $5.52M | -52.7% |
| 2017 | $11.68M | -27.9% |
| 2016 | $16.20M | -14.8% |
| 2015 | $19.00M | +25.8% |
| 2014 | $15.11M | -11.5% |
| 2013 | $17.07M | +25.2% |
| 2012 | $13.63M | +25.0% |
| 2011 | $10.90M | +12.6% |
| 2010 | $9.69M | -20.8% |
| 2009 | $12.23M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.44M | -14.8% | +95.5% |
| June 30, 2025 | $1.25M | -55.1% | -29.0% |
| March 31, 2025 | $1.76M | -36.4% | -38.6% |
| September 30, 2024 | $2.86M | +14.6% | +3.1% |
| June 30, 2024 | $2.77M | +95.3% | +0.4% |
| March 31, 2024 | $2.76M | -7.4% | +10.8% |
| September 30, 2023 | $2.49M | -15.3% | +75.6% |
| June 30, 2023 | $1.42M | -49.8% | -52.4% |
- PLUS THERAPEUTICS, INC. showed a decrease of -20.8% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, PLUS THERAPEUTICS, INC.’s r&d expense has declined by 31.5% (from $12.23 million to $8.38 million).
- The most recent figure is from PLUS THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: